TransMedics Group, Inc.

TransMedics Group, Inc. is a commercial-stage medical technology company dedicated to transforming organ transplant therapy for patients suffering from end-stage lung, heart, and liver failure. The company's mission is to save more lives by increasing access to viable donor organs, thereby enhancing organ utilization, improving patient outcomes, and reducing transplant costs. Headquartered in Andover, Massachusetts, TransMedics announced in January 2026 its plans for a new global headquarters and integrated campus in Somerville, Massachusetts.

The core of TransMedics' offerings is its proprietary Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system. Unlike traditional static cold storage, the OCS replicates near-physiologic conditions for donor organs outside the human body, allowing for warm perfusion, assessment, and optimization during transport. This innovative technology is the only FDA-approved system for lung, heart, and liver transplant indications in the U.S. Complementing the OCS technology, the company also provides the National OCS Program (NOP), an end-to-end service that includes donor organ retrieval, clinical management, and logistics, supported by a dedicated air and ground transportation network.

Founded in 1998 by Dr. Waleed Hassanein, who continues to serve as President and CEO, TransMedics maintains a leading position in the organ transplantation market. Recent developments include receiving full FDA IDE approval in early 2026 for its Next-Generation OCS ENHANCE Heart and DENOVO Lung trials. The company reported strong financial results for fiscal year 2025, with revenues reaching $605.5 million, a 37% year-over-year increase. In April 2026, TransMedics announced a strategic investment in PAD Aviation service GmbH to establish a dedicated European organ transplant logistics network, mirroring its successful U.S. NOP model. Furthermore, the company unveiled its Controlled Hypothermic Organ Preservation System (CHOPS) at ISHLT 2026, designed to enhance organ preservation techniques and support ongoing clinical trials.